Precigen Inc PGEN

NAS: PGEN | ISIN: US74017N1054 1/05/2025

1,550 USD (-0,64%)

(-0,64%) 1/05/2025

Grafiek Precigen Inc

Grafiek Precigen Inc

1 dag1d -0,64%
1 week1w 3,33%
1 maand1m 4,73%
3 maanden3m 19,23%
6 maanden6m 90,70%
1 jaar1j 10,71%
5 jaar5j -55,01%

Precigen Inc in het nieuws

Toon enkel gratis nieuws

16 april 2025 · Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th · Persbericht

19 maart 2025 · Precigen Reports Full Year 2024 Financial Results and Business Updates · Persbericht

13 maart 2025 · Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th · Persbericht

14 augustus 2024 · Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates · Persbericht

9 augustus 2024 · Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th · Persbericht

8 augustus 2024 · Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock · Persbericht

6 augustus 2024 · Precigen Announces Proposed $30 Million Public Offering of Common Stock · Persbericht

6 augustus 2024 · Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch · Persbericht

23 juli 2024 · Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch · Persbericht

3 juni 2024 · Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response · Persbericht

Profiel Precigen Inc

Gezondheidstechnologie

Website: www.dna.com

Hoofdzetel: Germantown, Maryland Verenigde Staten

CEO: Helen Sabzevari

Werknemers: 106

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe